Fluoropyrimidine-induced cardiotoxicity.

Area of Science:

• Cardio-oncology
• Pharmacology
• Cardiology

Background:

• Cardio-oncology focuses on managing chemotherapy-induced cardiotoxicity.
• Fluoropyrimidines are widely used cancer treatments with known cardiac risks.
• Fluoropyrimidine cardiotoxicity presents diverse symptoms, from angina to fatal events.

Purpose of the Study:

• To review the presentation of fluoropyrimidine-induced cardiotoxicity.
• To elucidate the mechanisms underlying this cardiotoxicity.
• To outline diagnostic and management approaches for fluoropyrimidine cardiotoxicity.

Main Methods:

• Literature review of studies on fluoropyrimidine cardiotoxicity.
• Analysis of reported cases and mechanisms.
• Synthesis of diagnostic criteria and treatment guidelines.

Main Results:

• Fluoropyrimidine cardiotoxicity manifests in various cardiac conditions.
• Mechanisms involve direct cellular damage, endothelial dysfunction, and coronary artery spasm.
• Early detection and tailored management are crucial for patient outcomes.

Conclusions:

• Understanding fluoropyrimidine cardiotoxicity is vital for safe cancer treatment.
• Multidisciplinary management involving oncologists and cardiologists is recommended.
• Further research into preventative strategies and novel treatments is warranted.